Cite
HARVARD Citation
Konstan, M. et al. (2017). Assessment of safety and efficacy of long-term treatment with combination lumacaftor and ivacaftor therapy in patients with cystic fibrosis homozygous for the F508del-CFTR mutation (PROGRESS): a phase 3, extension study. Lancet. 5 (2), pp. 107-118. [Online].